MTAP and Huntington disease: Consistently in multiple TCGA cancer cohorts, patients whose tumors had homozygous co-deletion of CDKN2A/MTAP and those who had HD of either gene had significantly shorter survival (Fig. 1g), with no statistical difference observed in the overall survival (OS) time among these three groups (Supplementary Fig. 2).